169 related articles for article (PubMed ID: 37694781)
1. Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR.
Chaudhary M; Kumar S; Kaur P; Sahu SK; Mittal A
Mini Rev Med Chem; 2024; 24(7):721-747. PubMed ID: 37694781
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
4. New approaches to targeting the androgen receptor pathway in prostate cancer.
Velho PI; Bastos DA; Antonarakis ES
Clin Adv Hematol Oncol; 2021 Apr; 19(4):228-240. PubMed ID: 33989272
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
7. A critical update on the strategies towards modulators targeting androgen receptors.
Luan H; Xu P; Meng Y; Li Z; Bian J
Bioorg Med Chem; 2020 Jul; 28(13):115554. PubMed ID: 32546299
[TBL] [Abstract][Full Text] [Related]
8. Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review.
Kim TJ; Lee YH; Koo KC
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805919
[TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
11. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
[TBL] [Abstract][Full Text] [Related]
12. Targeting continued androgen receptor signaling in prostate cancer.
Massard C; Fizazi K
Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
[TBL] [Abstract][Full Text] [Related]
13. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.
Crawford ED; Heidenreich A; Lawrentschuk N; Tombal B; Pompeo ACL; Mendoza-Valdes A; Miller K; Debruyne FMJ; Klotz L
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):24-38. PubMed ID: 30131604
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial update and novel therapeutic approaches for metastatic prostate cancer.
Larsson R; Mongan NP; Johansson M; Shcherbina L; Abrahamsson PA; Gudas LJ; Sterner O; Persson JL
Curr Med Chem; 2011; 18(29):4440-53. PubMed ID: 21864277
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth.
Helsen C; Marchand A; Chaltin P; Munck S; Voet A; Verstuyf A; Claessens F
Mol Cancer Ther; 2012 Jun; 11(6):1257-68. PubMed ID: 22496481
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Kim W; Ryan CJ
Curr Treat Options Oncol; 2012 Jun; 13(2):189-200. PubMed ID: 22539224
[TBL] [Abstract][Full Text] [Related]
17. Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives.
Xia QD; Zhang SH; Zeng N; Lu YC; Qin BL; Wang SG
Biomed Pharmacother; 2023 Dec; 168():115806. PubMed ID: 37925933
[TBL] [Abstract][Full Text] [Related]
18. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.
Leo J; Dondossola E; Basham KJ; Wilson NR; Alhalabi O; Gao J; Kurnit KC; White MG; McQuade JL; Westin SN; Wellberg EA; Frigo DE
Endocrinology; 2023 Apr; 164(6):. PubMed ID: 37154098
[TBL] [Abstract][Full Text] [Related]
19. Darolutamide: First Approval.
Markham A; Duggan S
Drugs; 2019 Nov; 79(16):1813-1818. PubMed ID: 31605368
[TBL] [Abstract][Full Text] [Related]
20. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
